HBED: A potential alternative to deferoxamine for iron-chelating therapy

Blood

Volumn 91, Issue 4, 1998, Pages 1446-1452

  Bergeron, Raymond J ^a   Wiegand, Jan ^b   Brittenham, Gary M ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032519770     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.4.1446     Document Type: Article

References (52)

1. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574, 1994
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567, 1994
3. Weatherall DJ: The treatment of thalassemia - Slow progress and new dilemmas. N Engl J Med 329:877, 1993
4. Cao A, Galanello R, Rosatelli MC, Argiolu F, De Virgiliis S: Clinical experience of management of thalassemia: The Sardinian experience. Semin Hematol 33:66, 1996
5. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematol 95:26, 1996
6. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: The benefits and limitations of desferrioxamine. Semin Hematol 32:304, 1995
7. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 89:739, 1997
8. Pippard MJ, Callender ST, Finch CA: Ferrioxamine excretion in iron-loaded man. Blood 60:288, 1982
9. Pippard MJ: Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol 2:323, 1989
10. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S: Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 21:640, 1993
11. Bergeron R, Streiff RR, King W, Daniels RD Jr, Wiegand J: A comparison of the iron-clearing properties of parabactin and desferrioxamine. Blood 82:2552, 1993
12. Bickel H, Hall GE, Keller-Schierlein W, Prelog V, Vischer E, Wettstein A: Metabolic products of actinomycetes. Ferrioxamine B. Helv Chim Acta 43:2129, 1960
13. Athanasiou A, Shep MA, Necheles TF: Anaphylactic reaction to desferrioxamine. Lancet 2:616, 1981
14. Miller KB, Rosenwasser LJ, Bessette JAM, Beer DJ, Rocklin RE: Rapid desensitization for desferrioxamine anaphylactic reactions. Lancet 1:1059, 1981
15. Bousquet J, Navarro M, Robert G, Aye P, Michel FB: Rapid desensitization for desferrioxamine anaphylactoid reactions. Lancet 2:859, 1983
16. Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F: Desferal (desferrioxamine) - A novel activator of tissue-type mast cells. J Allergy Clin Immunol 88:854, 1991
17. Patriarca G, Schiavino D, Nucera E, Pellegrino S, Valle D, Della Corte AM, Pagliari G: Successful desensitization of a child with desferrioxamine hypersensitivity. J Investig Allerg Clin Immunol 5:294, 1995
18. La Rosa M, Romeo MA, Di Gregorio F, Russo G: Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia. J Allergy Clin Immunol 97:127, 1996
19. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314:869, 1986
20. Benso L, Gambotto S, Pastorin L, Signorile F, Tanner JM: Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children. Eur J Pediatr 154:205, 1995
21. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ: Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 323:713, 1990
22. Kanno H, Yamanobe S, Rybak LP: The ototoxicity of deferoxamine mesylate. Am J Otolaryngol 16:148, 1995
23. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ: Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 14:48, 1992
24. Porter JB: Evaluation of new iron chelators for clinical use. Acta Haematol 95:13, 1996
25. Brittenham GM: Development of iron-chelating agents for clinical use. Blood 80:569, 1992
26. L'Eplattenier F, Murase I, Martell AE: Chelating tendencies of N,N' -Di(2-hydroxybenzyl)ethylenediamine-N',N'-diacetic acid. J Am Chem Soc 89:837, 1967
27. Grady RW, Hershko C: HBED: A potential oral iron chelator. Ann NY Acad Sci 612:361, 1990
28. Byoung-Koch K, Hubers HA, Finch CA: Effectiveness of oral iron chelators assayed in the rat. Am J Hematol 24:277, 1987
29. Pitt CG, Bao Y, Thompson J, Wani MC, Rosenkrantz H, Metterville JJ: Esters and lactones of phenolic and amino carboxylic acids: Prodrugs for iron chelation. J Med Chem 29:1231, 1986
30. Bergeron RJ, Streiff RR, Creary EA, Daniels RD Jr, King W, Luchetta G, Wiegand J, Moerker T, Peter HH: A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 81:2166, 1993
31. Peter HH, Bergeron RJ, Streiff RR, Wiegand J: A comparative evaluation of iron chelators in a primate model, in Bergeron RJ, Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton, FL, CRC Press, 1994, p 373
32. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Preliminary results from a Phase I clinical trial of HBED, in Bergeron RJ, Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton, FL, CRC Press, 1994, p 395
33. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Results from a phase I clinical trial of HBED. Adv Exp Med Biol 356:351, 1994
34. Hershko C, Grady RW, Link G: Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters. Haematologia (Budap) 17:25, 1984
35. Bergeron RJ, Wiegand J, Dionis JB, Egli-Karmakka M, Frei J, Huxley-Tencer A, Peter HH: Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J Med Chem 34:2072, 1991
36. Wood JK, Milner PF, Pathak UN: The metabolism of irondextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol 14:119, 1968
37. Bergeron RJ, Streiff RR, Wiegand J, Vinson JR, Luchetta G, Evans KM, Peter H, Jenny HB: A comparative evaluation of iron clearance models. Ann NY Acad Sci 612:378, 1990
38. Hider RC, Porter JB, Singh S: The design of therapeutically useful iron chelators, in Bergeron RJ, Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton, FL, CRC Press, 1994, p 353
39. 51Cr-labelled ethylenediaminetetraacetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability [published erratum appears in Clin Sci 71 (6):following xxi, 1986]. Clin Sci 71:71, 1986
40. Halliwell B: Free radicals and antioxidants: A personal view. Nutr Rev 52:253, 1994
41. Graf E, Mahoney JR, Bryant RG, Eaton JW: Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J Biol Chem 259:3620, 1984
42. Dean RT, Nicholson P: The action of nine chelators on iron-dependent radical damage. Free Radic Res 20:83, 1994
43. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neill R, Bacon BR: Pathophysiology of iron toxicity. Adv Exp Med Biol 356:239, 1994
44. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM: Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96:620, 1995
45. Carthew P, Dorman BM, Edwards RE, Francis JE, Smith AG: A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 69:217, 1993
46. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE: Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals 7:267, 1994
47. al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 91:224, 1995
48. Olivieri NF, Carmeron RG, Brittenham GM: Trials of the oral iron chelator L1. Ann NY Acad Sci (in press)
49. Grady RW, Hershko C: An evaluation of the potential of HBED as an orally effective iron-chelating drug. Semin Hematol 27:105, 1990
50. Hershko C, Grady RW, Link G: Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med 103:337, 1984
51. Borgna-Pignatti C, Cohen AR: An alternative method of subcutaneous desferoxamine administration. Blood 86:483a, 1995 (abstr, suppl 1)
52. Jensen PD, Jensen FT, Christensen T, Ellegaard J: Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol 89:880, 1995